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Induced pluripotent stem cells (iPSC) are a most promising approach to the development of a hepatocyte transplantable mass
sufficient to induce long-term correction of inherited liver metabolic diseases, thus avoiding liver transplantation. Their intrinsic
self-renewal ability and potential to differentiate into any of the three germ layers identify iPSC as the most promising cell-based
therapeutics, but also as drivers of tumor development. Teratoma development currently represents the gold standard to assess
iPSC pluripotency. We analyzed the tumorigenic potential of iPSC generated from human hepatocytes (HEP-iPSC) and compared
their immunohistochemical profiles to that of tumors developed from fibroblast and hematopoietic stem cell-derived iPSC. HEP-
iPSC generated tumors significantly presented more malignant morphological features than reprogrammed fibroblasts or CD34+
iPSC. Moreover, the protooncogene myc showed the strongest expression in HEP-iPSC, compared to only faint expression in the
other cell subsets. Random integration of transgenes and the use of potent protooncogenes such as myc might be a risk factor for
malignant tumor development if hepatocytes are used for reprogramming. Nonviral vector delivery systems or reprogramming of
cells obtained from less invasive harvestingmethods would represent interesting options for future developments in stem cell-based
approaches for liver metabolic diseases.
1. Introduction
Currently, the only treatment for inherited metabolic liver
diseases with severe extrahepatic manifestations consists of
liver transplantation (LT). Gene therapy of diseased hepato-
cytes followed by their autotransplantation is an alternative
approach to LT, as they allow correction of the metabolic
defect while avoiding immunosuppression and responding
to the shortage of donor livers. Yet the major obstacle for a
sufficient, long-term correction of the disease by this method
is the insufficient amount of autotransplantable hepatocytes.
One strategy for increasing the hepatocyte transplantable
mass would be the use of stem cells. Induced pluripotent
stem cells (iPSC) are endowed with intrinsic self-renewal
ability and the potential to differentiate into any of the three
germ layers and can thus be used to increase the hepatocyte
transplantable mass. However, the same properties that make
iPSC the most promising avenue for increasing HEP mass
also carry a risk of tumorigenicity.
In stem cell research, the gold standard assay for assessing
cell pluripotency is teratoma formation in immunosup-
pressed mice. Teratomas are benign tumors characterized
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by their rapid growth in vivo and a haphazard mixture of
somatic tissues at varying degrees of differentiation [1]. In
fact, this assay is used to check the ability of iPSC to form
the three germ layers in vivo. The presence of immature
elements, and mostly of primitive neuroectodermal rosettes,
defines immature teratoma. These lesions are potentially
malignant. Primitive germ cell tumors consist of tumors that
contain malignant germ cell elements other than teratoma,
namely, dysgerminoma/seminoma, yolk sac tumor, embry-
onal carcinoma, and nongestational choriocarcinoma [2].
Teratomas derived from engrafted iPSC may show primitive
neuroectodermal rosettes that may be accompanied by yolk
sac elements.
The use of oncogenes such as myc during the repro-
gramming of human somatic cells to iPSC is of particular
interest since not only is MYC a notable example of proteins
known to interfere with normal cell differentiation, but also
overexpression of MYC targets is observed in poorly differ-
entiated and aggressive human tumors [3]. Moreover, an
influence of the tissue of origin in teratoma-forming propen-
sity has been shown [4].
Nevertheless, few studies have examined teratoma forma-
tion for preclinical safety [5]. According to some authors, yolk
sac elements may have been overlooked and underreported
and malignant embryonal carcinoma cells have rarely been
described in xenografts derived from human iPSC [5, 6]. On
the other hand, little is known about the profile of expression
of tumoral markers in vivo. Thus, a better understanding of
the biology of iPSC and cellular reprogramming will highly
contribute to the development of new strategies for safe
treatments.
It has been described that iPSC keep the epigenetic
memory of the cells of origin [7]. Focusing on the transla-
tional application of iPSC for liver diseases, for example, cell
transplantation for the treatment of inherited metabolic liver
disease, human hepatocytes would thus presumably be the
best cell source for reprogramming. Therefore, we analyzed
the tumorigenic potential of iPSC generated from human
primary hepatocytes and compared histological findings and
immunohistochemical profiles to those of tumors developed
from foreskin fibroblast- andhematopoietic stem cell-derived
iPSC as more accessible sources of cells.
2. Materials and Methods
2.1. Cells. Primary human hepatocytes were obtained from
patients treated in the Swiss Center for Liver Diseases in
Children at the Geneva University Hospitals after having
obtained their parents’ written consent. Cells were extracted
from the child’s native liver after they had undergone total
hepatectomy as previously described [8]. Ethical approval for
the cell isolation was obtained from the institutional ethics
committee (approval number 08-028). Human foreskin
fibroblasts were obtained from ATCC biological resources
center (Manassas, USA). CD34+ cells from human cord
blood were obtained and prepared as previously described
[9].
2.2. Human iPSC Reprogramming. The polycistronic excis-
able reprogramming vector STEMCCA (hereafter called
OKSM) was kindly provided by Professor Mostoslavsky
(Boston University, MA, USA) [10]. Lentiviral particles
encoding Oct-4, Klf4, Sox2, and Myc were prepared as
previously described in [8]. The lentiviral vector expressing
POU5F1 (OCT4), KLF4, and SOX2 as a single polycistronic
transcript (hereafter called OKS) was kindly provided by
Professor Naldini [11].
5 × 105 human primary hepatocytes were plated on Mat-
rigel or collagen before being transduced with OKS or OKSM
using a MOI of 20. The same numbers of human foreskin
fibroblasts were transduced with OKSM at MOI of 20. After
5 days, cells were switched to mTeSR1 medium (STEMCELL
Technologies) and grown until reprogrammed colonies
emerged (∼20 days). 2.5 × 105 CD34+ cells were transduced
with OKS using 100 HC-TU per cell. After 5 days, cells
were switched to mTeSR1 medium and grown on a mouse
fibroblast feeder layer until reprogrammed colonies emerged
(∼21 d). Individual human iPSC clones were then picked and
expanded on Matrigel-coated plates in mTeSR1 medium.
2.3. Mouse iPSC Reprogramming. Mouse hepatocytes and
hematopoietic stem cells were obtained from transgenic mice
in which the four reprogramming transcription factors were
stably integrated as a single doxycycline-inducible poly-
cistronic cassette within the ubiquitously expressed Rosa26
locus (ROSA)26Sor [12]. Hepatocytes and hematopoietic cells
were isolated as previously described in [8, 9]. iPSC gener-
ation was induced upon addition of doxycycline (2 𝜇g/mL)
during 12 days. iPSC clones were then manually picked
and expanded on gelatin-coated plates in Glasgow MEM
(SIGMA) 15% FBS supplemented with 5% NEAA (Gibco),
100 𝜇M b-mercaptoethanol, 1mM sodium pyruvate (Gibco),
and 1000U/mL of LIF (leukemia inhibitory factor (Chemi-
con)).
2.4. iPSC Characterization. Expression of pluripotency
markers was addressed by immunofluorescence. iPSC were
plated on Matrigel-coated glass coverslips. Before staining,
coverslips were rinsed once with PBS and fixed for 15minutes
with 4% paraformaldehyde (PFA). Cells were rinsed 3 times
with PBS for 5 minutes, blocked with 3% bovine serum
albumin (BSA), and permeabilized with 0.3% Triton 9 X-100
in PBS for 1 h. Primary antibodies at appropriate dilutions
were incubated ON at 37∘C in PBS containing 0.1% Tween-20
and 1% BSA. Secondary antibodies at appropriate dilutions
were incubated for 1 hour at 37∘C together with DAPI
1 : 400. Finally, cells were washed and mounted onto glass
slides with Mowiol and left overnight in the dark at room
temperature (RT) before observation under the microscope.
The kit of primary antibodies StemLight Pluripotency Kit
(Cell Signaling Technology), which includes antibodies
against Oct4, Sox2, Nanog, SSEA4, and Tra-1-60, was
used. Secondary antibodies were donkey anti-mouse Alexa
Fluor 488 and donkey anti-rabbit Alexa Fluor 536 (Life
Technologies). Images were visualized with a Zeiss Axiophot
Stem Cells International 3
microscope (Carl Zeiss) equipped with an Axiocam camera
(Carl Zeiss); confocal images were obtained using the LSM
510 laser scanning confocal microscope (Carl Zeiss).
Embryoid bodies from the different clones were gener-
ated using the AggreWell plates and followingmanufacturers’
instructions (STEMCELL Technologies). Karyotype analysis
in all the iPSC clones following the G-banding method was
performed by the Service of Cytogenetics of the University of
Geneva.
1 × 106 cells from the different iPSC clones at passage 3
in 100 𝜇L of Matrigel-PBS mix (1 : 1) were injected in a sub-
cutaneous or intratesticular location in NOD/SCID mice to
induce teratoma formation. Human embryonic stem (hES)
cells were injected as a control. Three animals were injected
per clone. Mice were sacrificed after 3 to 8 weeks, according
to tumor size and development. Tumors were fixed in 10%
buffered formalin for 48 h.
2.5. Histology, Immunohistochemistry, and In Situ Hybridiza-
tion. Histological analysis was performed to assess teratoma-
forming potential and tumor components. Specimens were
entirely submitted for histological analysis, after gross pro-
cessing and paraffin-embedding. Hematoxylin and Eosin
(H&E) stains were performed on 3𝜇m thick sections of the
paraffin-embedded tissue.
Immunohistochemistry was conducted on selected
tumors. High temperature antigen retrieval was applied.
Reactivity to primary antibodies was identified using the
Ultravision detection system and DAB as the chromogen
substrate (Thermo Fisher Scientific) for the following
antibodies: 𝛽-catenin (Novocastra mouse monoclonal, clone
17C2; dilution 1 : 20); CD30 (Dako mouse monoclonal, clone
Ber-H2; prediluted); pooled cytokeratins (CK): AE1/AE3 +
CK8/18 (Dako mouse monoclonal and rabbit monoclonal;
AE1/AE3 dilution 1 : 100, CK8/18 1 : 25); Glypican 3, GPC3
(Cell Marque mouse monoclonal, clone 1G12; dilution 1 : 20);
sal-like protein 4, SALL4 (BioCare Medical mouse mono-
clonal, clone 6E3; 1 : 100 dilution). The Envision visualization
system (Dako) and DAB as the chromogen substrate were
used for the remaining antibodies used: Alpha Fetoprotein,
AFP (Novocastra, clone C3 mouse monoclonal; dilution
1 : 750); Chorionic Gonadotropin, 𝛽-subunit, 𝛽-HCG (Dako
rabbit polyclonal; dilution 1 : 20); MYC (Abcam rabbit mono-
clonal, clone Y69; dilution 1 : 50); OCT4 (Abcam mouse
monoclonal, clone SEMGC; dilution 1 : 2); and Placental
Alkaline Phosphatase, PLAP (Dako mouse monoclonal,
clone 8A9; dilution 1 : 10).
Albumin in situ hybridization was performed as previ-
ously described [13]. Briefly, a PCR template coding for the
nearly full-length human albumin was generated from the
MGC clone containing the complete cDNA for the human
protein, purchased from Invitrogen (Invitrogen, Carlsbad,
USA).
2.6. Immunohistochemistry Antibodies and
In Situ Hybridization Probe
2.6.1. SALL4. SALL4, a zinc-finger transcription factor, is a
master regulator of embryonal pluripotency. Expressed in
ES cells, SALL4 interacts with other pluripotency-related
transcription factors such as OCT4 and NANOG. Whereas
SALL4 is expressed in various fetal tissues, in adults only
normal spermatogonia display reactivity. SALL4 has been
identified as a useful immunohistochemical marker for germ
cell tumors, being strongly expressed in seminoma, embry-
onal carcinoma, and yolk sac tumor. Focal reactivity is seen
in choriocarcinoma, and limited expression is observed in
differentiated teratoma components [14].
2.6.2. OCT4. OCT4 (OCT3/4, the product of the POU5F1
gene) is a transcription factor expressed in primordial germ
cells and ES cells and is the most crucial POU domain trans-
cription factor responsible for the maintenance of pluripo-
tency and self-renewal. OCT4 nuclear expression is observed
in ES cells and primordial germ cells during normal embryo-
genesis [15]. In germ cell tumors, OCT4 immunohistochemi-
cal expression is 100% sensitive for seminoma/dysgerminoma
and embryonal carcinoma, whereas it is negative in yolk sac
tumor and choriocarcinoma. Reactivity has also been shown
in the immature neuroepithelium of high-grade immature
teratoma [16].
2.6.3. MYC (CMYC). The MYC protein, per se a relatively
weak transcriptional activator, influences numerous genes
encoding proteins involved in cell cycle regulation, cell
growth, metabolism, ribosome biogenesis, protein synthesis,
and mitochondrial function. Mitogenic stimulation of quies-
cent cells induces rapid increases in MYC levels. In cancer,
frequent MYC deregulation may occur by chromosomal
translocation or gene amplification. Deregulation may also
occur at the level of MYC mRNA and protein expression or
stability (reviewed in [17]).
In different non-Hodgkin’s lymphoma subtypes, MYC
protein expression shows good correlation with the presence
of MYC genetic translocations and has also major clinical
implications [18].
2.6.4. CD30 and PLAP. Among other immunohistochemical
markers used for embryonal carcinoma, CD30, a member of
the tumor necrosis factor receptor family, shows reactivity
in 93% to 100% of embryonal carcinomas [19]. PLAP occurs
focally as amembranous and/or cytoplasmic staining inmost
embryonal carcinomas; staining may also be seen in approx-
imately half the yolk sac tumors and choriocarcinomas.
2.6.5. GPC3. GPC3 is a membrane-anchored member of the
glypican family of heparin sulfate that may play a role in pro-
moting embryonic cell growth and differentiation. Among
germ cell tumors, GPC3 has been shown to be expressed in
all yolk sac tumors, usually displaying a moderate-to-strong
and diffuse pattern of staining. Choriocarcinoma is also con-
sistently positive, with strong staining in themalignant syncy-
tiotrophoblasts and weaker staining in the cytotrophoblasts.
In about one-third of the cases, immature teratomamay show
variable reactivity in the primitive stroma, neuroepithelium,
fetal-type glands, primitive tubules, and cartilage anlage.
GPC3 is rarely expressed in embryonal carcinoma [20].
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2.6.6. AFP. AFP, a major plasma protein produced by the
yolk sac and liver during fetal life, shows reactivity in about
85% of yolk sac tumors; AFPmay also be positive in scattered
cells in embryonal carcinoma. Contrary to the diffuse GPC3
pattern of staining in yolk sac tumors, AFP reactivity is often
focal [19]. AFP is also expressed in the normal secondary
human yolk sac that also shows reactivity to GPC3 and
SALL4.
2.6.7. 𝛽-Catenin. 𝛽-catenin is a multifunction protein that
acts as a component of the cell-cell adhesion apparatus. In the
nucleus 𝛽-catenin acts as a coactivator of the transcription
of T-cell transcription factor/lymphoid enhancer binding
factor (TCF/LEF) target genes, allowing for the recruitment
of factors required for chromatin remodeling and transcrip-
tional activation. Immunohistochemical 𝛽-catenin nuclear
accumulation is observed in various tumor models and
indicates deregulation of the Wnt pathway.
2.6.8. Albumin. Albumin synthesis occurs in the liver, and
human fetuses synthesize endogenous albumin from early
pregnancy on [21]. Therefore, albumin detection represents
a marker of hepatocyte differentiation. Of note, the hepatoid
variant of yolk sac tumor may also express albumin [22],
again in line with a marker of differentiation.
3. Results
3.1. General Pathology Findings. iPSC were generated from
different human cell sources: hepatocytes, fibroblasts, and
hematopoietic stem cells. Clones were characterized by
immunofluorescence before injection, and expression of
pluripotency markers was confirmed (Figures 1(a)–1(e)). The
ability of the stable clones to generate the three germ layers in
vitro was analyzed showing accurate embryoid body forma-
tion (Figure 1(f)). Besides, analysis of the karyotype of each
clone was performed in order to discard any chromosomal
aberration (Figure 1(g)). No differences among clones in the
levels of pluripotent protein expression or embryoid body
formation were observed.
The generated iPSC clones allowed for varying degrees of
teratoma formation. The presence of immature, embryonal-
type, or primitive tissue (generally neuroectodermal rosettes)
identified immature teratoma. No dysplasia was seen in the
teratoma epithelial components. Immunohistochemistry was
performed to compare reactivity with known protein expres-
sion profiles in human germ cell tumors. Of note, no tumor
displayed syncytiotrophoblastic cells, and 𝛽-HCG, a dimeric
glycoprotein produced by placental trophoblastic cells and
the main choriocarcinoma immunohistochemical marker,
remained negative in all tumors assessed. Staining for 𝛽-
catenin showed amembranous pattern of staining exclusively
and no nuclear delocalization.Histological findings andmain
immunohistochemical results are summarized in Table 1.
hES cells injected as a control of teratoma formation in
a subcutaneous and an intratesticular location generated as
expected partly cystic and partly solid teratomas (Figures
2(a) and 2(b)), composed of structures derived from all
three germ layers. Large cystic glands were separated by
loose mesenchymal septa, in which a few slightly immature
glandular structures were embedded (Figure 2(c)). Deriva-
tives from the ectodermal layer (neuroectodermal rosettes
and pigmented epithelium) and from the mesodermal layer
(cartilage) were also seen (Figure 2(d)). In one tumor, a
second portion consisted of a small and solid 0.2 cm nodule,
located in an intramuscular position at a distance of 0.2 cm
from the main cystic portion (Figure 2(e)). The nodule
was composed of immature neuroglial tissue, cartilage, and
glands (Figure 2(f)). A minority of the glandular structures
showed nuclear atypia, increased apoptotic rate, but no
mitoses (Figure 2(g)). MYC reactivity was however faint
and focal, expressed in approximately 20% of the atypical
cells (Figure 2(h)). Whereas SALL4 reactivity was strong,
there was no reactivity to OCT4, CD30, or PLAP, thereby
disproving embryonal carcinoma.
3.2. iPSC Generated from Human Hepatocytes. Seven clones
were generated from human primary hepatocytes; five were
subcutaneously injected and two in the mouse testis.
When hepatocytes were reprogrammed to iPSC using
the OKS integrative vector, tumors were relatively small
(up to 1 cm in greatest diameter) and either in part cystic
(Figure 3(a)) or composed of loosely arranged tissues. No
tumor development was observed after 9 weeks in the three
mice injected with one of the OKS clones. Histologically,
all three tumors from the second clone showed features of
immature teratoma, with development of derivatives from
all three primary germ layers. Ectodermal derivatives were
mainly mature, with rare neuroectodermal rosettes in only
one of the three tumors, representing less than 5% of the
tumor volume. Mesodermal derivatives consisted of bone
(Figure 3(b)), adipose tissue, and mesenchymal cells at vary-
ing degrees of maturation. Endoderm-derived structures
consisted of variably immature glands and fetal-type hepa-
tocytes (Figure 3(c)). In one tumor, confluent atypical glan-
dular structures showed stratification. The cells displayed a
high nucleocytoplasmic ratio, with large and hyperchromatic
nuclei; apoptotic bodies were numerous, and minute foci of
necrosis were seen (Figure 3(d)); stratified glands were also
focally close to nests of fetal-like hepatocytes (Figure 3(e)).
Upon immunohistochemical evaluation, pooled cytokeratins
highlighted the epithelial structures and showed more mod-
erate reactivity in the atypical glands. The latter also strongly
expressed SALL4 and OCT4 (Figures 3(f) and 3(g)). Mild
reactivity was seen forMYC (Figure 3(h)) andCD30, whereas
PLAP remained negative. Epithelial structures and aminority
of the atypical glands (20%) showed strong GPC3 reactivity.
The fetal-appearing hepatocytes expressed AFP (Figure 3(i))
and GPC3 and were also decorated by albumin (Figure 3(j)).
Most of the clones reprogrammed with the OKSM
lentiviral vector produced tumors composed of a major
embryonal carcinoma-like component (5/6). Three of four
clones injected subcutaneously induced solid tumors larger
than 1 cm in less than 4 weeks. All displayed malignant
histological features, being composed nearly exclusively
(95% or more) of an embryonal carcinoma-like compo-
nent. The pattern of growth was mostly solid, with an
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Figure 1: iPSC characterization. (a–e) Immunofluorescence shows the protein expression of the pluripotency markers NANOG, OCT4,
SOX2, SSEA4, and TRA-1-60 (10x). (f) Embryoid body formation by the clones shows generation of the three germ layers in vitro. (g)
Karyotyping showed no chromosomal aberration.
intimately admixed minor component of irregular gland-like
spaces (Figure 4(a)). Tumor cells formed serpiginous ribbons
around central foci of tumor necrosis and were focally
lined by fibrovascular septa or by minute foci of immature
mesenchymal cells (Figure 4(b)). Tumor cells were large and
primitive-appearing, with vesicular nuclei and prominent
nucleoli (Figure 4(b), inset). Mitoses, some of which are
atypical, and apoptotic bodies were numerous. Intravascular
tumor embolism was seen (Figure 4(c)). Gland-like spaces
formed a minor tumor component (Figure 4(d)). Nuclear
expression of SALL4 (Figure 4(e)) and of the pluripotency
marker OCT4 (Figure 4(f)) was strong and diffuse, whereas
membranous and cytoplasmic PLAP reactivity (Figure 4(g))
was seen in 70% or more of the cells, with varying intensity.
Membranous staining for CD30 was moderate to strong
(Figure 4(h)). However, nests of negative cells were high-
lighted by this staining, appearing even more primitive and
rounded. Contrary to the embryonal carcinoma cells, these
cells forming gland-like spaces expressed GPC3 (Figure 4(i))
and AFP (Figure 4(j)) and showed stronger reactivity for
pooled cytokeratins than the embryonal carcinoma com-
ponent (Figure 4(k)). The morphological features and the
immunohistochemical pattern of expression were consistent
with aminor yolk sac tumor component.Moderate-to-strong
MYC nuclear reactivity (Figure 4(l)) was seen only in the
embryonal carcinoma cells.
The two hepatocyte-derived clones injected in the testis
also produced large tumors.One of the tumorswas composed
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Figure 2: Human embryonic stem cells and teratoma formation. Teratomas generated were partly cystic (a) and partly solid (b) (Hematoxylin
and Eosin (H&E), original magnification 20x). Tumors were composed of structures derived from all three germ layers; cystic glands were
divided by paucicellular mesenchymal septa, in which a few slightly immature glandular structures were embedded (c, H&E 200x). Glands
(arrows) and immature cartilage plates (stars) are shown as derivatives from the endodermal and mesodermal layers, respectively (d, H&E
200x). In one tumor, a small and solid 0.2 cm nodule (arrow) was located in an intramuscular position at a distance of 0.2 cm from the
main cystic portion and close to the mouse vas deferens (arrowhead) (e, H&E 20x). The nodule was composed of immature neuroglial tissue
(arrowhead), cartilage (star), and glands; a minority of the glandular structures were atypical (arrow) (f, H&E 100x). At higher magnification
(g,H&E200x), these glandswere formedof cells showingnuclear atypia and increased apoptotic rate.Upon immunohistochemical evaluation,
MYC reactivity was faint and focal, expressed in approximately 20% of the atypical cells (h, 200x).
nearly exclusively of embryonal carcinoma, with only minute
foci of immature mesenchyme. The second clone produced
mixed germ cell tumors, made of teratoma and embryonal
carcinoma, the latter representing 40 to 60% of the tumor.
Immunohistochemical profile in the embryonal component
was similar to the clones injected subcutaneously, except for
mild GPC3 staining and absence of AFP reactivity. Immature
teratomawas also seen in the tumors generated by this second
clone, with derivatives from the three germ layers; however,
no liver differentiation was seen.
The only clone differing from the above-mentioned
clones was injected subcutaneously and produced partly
cystic and partly solid tumors, measuring up to 1 cm in
greatest diameter after 6 weeks. The tumors corresponded to
mixed germ cell tumors with immature teratoma, embryonal
carcinoma, and small foci of yolk sac tumor. The immature
teratoma component contained derivatives from all three
germ layers, of which neuroectodermal rosettes represented
around 10%. Another 10% of the tumors were composed of
embryonal carcinoma, strongly reactive to SALL4, OCT4,
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Figure 3: iPSC generated from human hepatocytes, using the OKS integrative vector. The tumors produced were in part cystic (a, H&E 20x)
and showed features of immature teratoma. Fibrous bone was part of the mesodermal derivatives and was surrounded by loosely arranged
mesenchymal cells (b, H&E 200x). Endoderm-derived structures consisted of variably immature glands focally in close relationship to fetal-
like hepatocytes (arrow) (c, H&E 200x). Rarely, confluent atypical glandular structures showed stratification (d, H&E 100x); stratified glands
(arrow) were also focally close to nests of fetal-like hepatocytes (arrowhead) (e, H&E 400x). Upon immunohistochemical evaluation, the
atypical glands displayed strong expression of SALL4, a feature shared by some of the teratoma components of which the hepatocyte plates
are (arrowheads) (f, 200x). Strong reactivity to OCT4 was also seen (g, 200x). MYC reactivity was only mild (h, 200x). The fetal-appearing
hepatocytes expressed AFP (i, 200x) and albumin (j, in situ hybridization, 200x).
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Figure 4: iPSC generated from human hepatocytes, using the OKSM integrative vector. The generated tumors were mostly solid, with an
intimately admixed minor component of irregular gland-like spaces (arrow); tumor cells formed serpiginous ribbons around central foci
of tumor necrosis (star) (a, H&E 20x). Rarely, minute foci of immature mesenchymal cells were seen (arrow) (b). The major component
was composed of pleomorphic malignant-appearing embryonal carcinoma cells that were large and primitive-appearing, with vesicular
nuclei and prominent nucleoli; mitoses (arrow) and apoptotic bodies (arrowheads) were numerous (b, inset, H&E 400x). Gland-like spaces
lined by immature cells were focally seen and corresponded to a minor yolk sac tumor component (arrows) (c, H&E 100x). Intravascular
tumor embolism from the embryonal carcinoma component, a further malignancy criterion, was seen (d, H&E 200x). In the embryonal
carcinoma component, strong and diffuse nuclear expression of SALL4 (e, 200x) and OCT4 (f, 200x) was seen, as well as moderate-to-strong
membranous and cytoplasmic PLAP (g, 200x), and CD30 (h, 200x) reactivity. Contrariwise, the yolk sac component showed strong GPC3 (i,
200x) and AFP (j, 200x) reactivity. Pooled cytokeratins were expressed in both components but strongly in the yolk sac glandular structures
compared to in the embryonal carcinoma component (k, 200x). MYC nuclear reactivity was seen exclusively in the embryonal carcinoma
cells (l, 200x).
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Figure 5: iPSC generated from human fibroblasts.The tumors generated weremainly cystic (a, H&E 20x), and derivatives from all three germ
cell layers were seen. Intestinal type structures were lined by amucin producing epithelium, overlying a well-differentiated wall with a smooth
muscle layer (b, H&E 100x). Mesodermal derivatives also consisted of immature bone (osteoid) (arrowhead) and cartilage (star), as well as
striated muscle (arrow) (c, H&E 100x). Ectodermal derivatives corresponded mainly to immature neuroglial tissue and neuroectodermal
rosettes (arrows) (d, H&E 200x).
and PLAP, and showingmoderate expression of CD30. GPC3
reactivity was mild and focal. MYC staining was strong.
3.3. iPSC Generated from Human Fibroblasts. All the
tumors from fibroblast-derived clones were mainly cystic
(Figure 5(a)). Derivatives from all three germ cell layers were
seen (Figures 5(b) and 5(c)), the ectodermal derivatives corre-
spondingmainly to immature neuroglial tissue and neuroect-
odermal rosettes (Figure 5(d)), identified as a minor compo-
nent (with a maximum of 10%). No embryonal carcinoma-
like foci were seen. No differences were observed between
the tumors injected subcutaneously and in the testis.
3.4. iPSC Generated from CD34+ Hematopoietic Stem Cells.
All the clones derived from CD34+ hematopoietic stem
cells were generated with the OKS lentiviral vector and
subcutaneously injected. Tumors were immature teratoma,
with derivatives from the 3 germ layers in 2/3 of the cases.
A third clone produced a more solid tumor (Figure 6(a)),
with only rare neuroectodermal rosettes, and minute foci
of immature mesenchymal cells; primitive structures were
reminiscent of endodermal sinus. This yolk sac component
was composed of a loose meshwork of primitive-appearing
cells lining cystic spaces (Figure 6(b)). More than 90% of
the tumor was composed of pluristratified glandular and
vesicular structures, showing nuclear atypia, and high apop-
totic and mitotic rates; small foci of necrosis were seen.
SALL4 showed strong and diffuse staining; the small focus
with neuroectodermal rosettes was however lost on the slide
used for this marker. Strong albeit focal reactivity for GPC3
(Figure 6(c)) and AFP (Figure 6(d)) was seen in the yolk
sac tumor component. Pooled cytokeratins were negative in
the neuroectodermal rosettes and expressed in the epithe-
lial structures with varying intensities, as well as in some
spindle cells in the mesenchymal septa. Reactivity for OCT4
(Figure 6(e)) highlighted the embryonal carcinoma foci but
was negative in both the endodermal sinus derivatives (yolk
sac tumor foci) and the neuroectodermal rosettes. Aminority
of the embryonal carcinoma cells expressed CD30 and PLAP,
whereas MYC staining was moderate in the embryonal
carcinoma cells and mild and focal in the neuroectodermal
rosettes; no reactivity was seen in the endodermal sinus
structures (Figure 6(f)). The differential MYC activation and
expression in this clone reprogrammed with the lentiviral
vector encoding only Oct4, Sox2, and Klf4 could be due to
insertional mutagenesis.
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Figure 6: iPSC generated from CD34+ hematopoietic stem cells. One of the three clones produced a partly solid tumor mainly composed
(95%) of an embryonal carcinoma component (a, H&E 20x), with only rare neuroectodermal rosettes (arrow) and a minor yolk sac
component (arrowheads). The yolk sac component consisted in a loose meshwork of primitive-appearing cells lining cystic spaces (arrow:
neuroectodermal rosettes) (b, H&E 100x). Whereas strong reactivity for GPC3 (c, 200x) and AFP (d, 200x) was seen in the yolk sac tumor
component, reactivity for OCT4 (e, 200x) highlighted the embryonal carcinoma component only. MYC staining was moderate in the
embryonal carcinoma cells, whereas no reactivity was seen in the yolk sac component (f, 200x).
3.5. iPSC Generated from 4F2A Transgenic Mouse Cells. In
order to evaluate the effect of insertional mutagenesis of the
reprogramming transgene, additional clones were derived
from mouse hepatocytes and hematopoietic stem cells from
the transgenic 4F2A mice harboring the classic four tran-
scription factors stably integrated as a single doxycycline-
inducible polycistronic cassette within the ubiquitously
expressed Rosa26 locus.
All iPSC from hepatic origin produced mixed germ cell
tumors with only minor embryonal carcinoma components
(5% to 10%) together with teratoma, showing derivatives
from all three germ layers (Figures 7(a)–7(c)). Small foci of
fetal-type hepatocyte plates were radially arranged around
a vein, reminiscent of pericentrilobular vein architecture
(Figure 7(d)). The embryonal carcinoma cells were arranged
in cords and gland-like structures, forming small dispersed
nests within the teratoma component (Figure 7(e)). Strong
nuclear reactivity was seen for SALL4 (Figure 7(f)), whereas
OCT4 reactivity was moderate and focal (Figure 7(g)). A
striking difference with the human-derived cell lines was
that MYC nuclear reactivity was faint in approximately 30%
of the cells and moderate in rare nuclei (less than 1%);
very faint nuclear staining was also observed in a minority
of the neuroglial cells, in the abundant glial component
(Figure 7(h)). AE1/AE3 keratin reactivity was confined to the
more differentiated epithelial structures.
Mouse hematopoietic stem cell-derived clones produced
large solid tumors, consisting in immature teratomas, with
structures derived from all three germ layers (Figures 8(a)
and 8(b)). Neuroglia was usually abundant and more mature
than in the other tumor models. Endodermal derived struc-
tures were also more differentiated. One clone also produced
minute foci of yolk sac tumor, and all three clones showed
a minor embryonal carcinoma component (representing 5%
to 10% of the tumor volume), often closely related to imma-
ture neuroglial tissue (Figure 8(c)). However, MYC immuno-
histochemical reactivity was also faint and focal in these
embryonal carcinoma foci (Figure 8(d)).
4. Discussion
iPSC not only offer a promising source of pluripotent cells
for regenerative medicine purposes, but also provide insights
in the tumorigenic mechanisms of germ cell tumors, a
tumor model associated with particular developmental-like
differentiation processes.
In the 2014 WHO Classification of Tumours of Female
Reproductive Organs [2], germ cell tumors comprise dys-
germinoma, yolk sac tumor, embryonal carcinoma, nonges-
tational choriocarcinoma, mature teratoma, immature ter-
atoma, and mixed germ cell tumors. In the testis, the tera-
toma category also comprises dermoid cyst, monodermal
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Figure 7: iPSC generated frommouse hepatocytes. All iPSCwithmouse hepatic origin produced solidmixed germ cell tumors (a, H&E 20x).
The teratoma components showed derivatives from all three germ layers, with development among other endodermal structures of ducts and
pancreas (arrow) (b, H&E 200x), of cartilage as mesodermal derivative (star) (c, H&E 200x) and neuroglial tissue as ectodermal derivative
(arrow) (c). Fetal-type hepatocyte plates were focally radially arranged around a centrilobular-like vein (arrowhead) (d, H&E 200x). A minor
embryonal carcinoma component was composed of tumor cells arranged in cords and gland-like structures and forming small dispersed
nests (star) within the neuroglial component (arrow); ganglion-like cells (arrowheads) are also seen (e, H&E 200x). Strong nuclear reactivity
to SALL4 (f, 200x) andOCT4 (g, 200x)was seen in the embryonal carcinoma cells.MYCnuclear reactivitywas faint and focal in the embryonal
carcinoma component andmoderate only in less than 1% of the cells (arrowheads); a minority of the neuroglial cells (arrow) also showed very
faint nuclear staining (h, 200x).
teratoma, and teratoma with somatic type malignancies;
immature teratoma is not a recognized category. Tumors
showing mixed features are considered as tumors of more
than one histological type or mixed forms [23]. Yolk sac
tumor and choriocarcinoma resemble extraembryonic tis-
sues [24].
Differences in nomenclature between the clinical and
fundamental research settings may be confusing. A human
testicular or ovarian tumor associatingmixed embryonal car-
cinoma and teratoma would be considered a mixed germ cell
tumor, whereas a similar tumor would be called teratocarci-
noma in a murine setting [25]. In an attempt to clarify the
confusion in terminology, the position by Nature Biotech-
nology was to consider “teratocarcinoma” as a malignant
tumor composed of both somatic tissues and undifferentiated
embryonal carcinoma cells [26].
4.1. General Features of iPSC Tumors. Teratoma formation
after iPSC transplantation is thought to result from resid-
ual undifferentiated cells contained within the transplanted
cells [27]. On the other hand, embryonal carcinoma cells
represent the multipotential and undifferentiated malignant
stem cells of “teratocarcinoma” [28]. Under nonneoplastic
conditions, they can undergo self-renewal or differentiate
into multiple mature cells types, a feature shared by ES
cells. Interestingly, most of the reprogrammed iPSC clones
in our study showed at least 5% of residual undifferentiated
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Figure 8: iPSC generated from mouse hematopoietic stem cells. Tumors produced were mainly solid mixed germ cell tumors (a, H&E
20x). The teratoma component showed derivatives from all three germ layers (b, H&E 100x), with the ectodermal (neuroglial, star) and
endodermal (squamous epithelium, arrow, and exocrine pancreas, vertical arrowheads) derivatives being shown; small foci of embryonal
carcinoma (horizontal arrowheads) were intermingled. At higher magnification (c, H&E 200x), the embryonal carcinoma cells formed small
dispersed nests (star) within the teratoma component (immature neuroglial tissue, arrow). MYC immunohistochemical reactivity was very
faint and focal in the embryonal carcinoma foci (d, 200x).
cells, which means that they are mixed germ cell tumors.
Unfortunately, this pathological description of the iPSC is
often underreported due to the fact that researchers normally
look for histological structures of differentiated cells when
characterizing the clones. For their use as an alternative to
liver transplantation in inborn liver metabolic diseases, iPSC
will be differentiated to hepatocytes before transplantation.
However, differentiation protocols are not 100% efficient and
even though it has been described that embryonal carcinoma
cell lines have limited growth, we should keep in mind
this percentage of malignant potential. Furthermore, similar
to a majority of human embryonal carcinomas, the stem
cells of human embryonal carcinoma cells express CD30, a
feature that has been clearly associated with decreased levels
of apoptosis [29]. Induction of karyotype abnormalities in
hES cells, with gain of an extra copy of chromosome 12, is
paralleled with the acquisition of CD30 expression and the
generation of teratomas exhibiting a more primitive, undif-
ferentiated phenotype [29].
4.2. OKSM-Derived iPSC Tumors. In those iPSC clones
generated from hepatocytes with the OKSM lentiviral vec-
tor, the embryonal carcinomas were completely solid and
undifferentiated and tumors did not showother differentiated
components. Only one clone of that subset generated a ter-
atoma with 5–10% of expected residual undifferentiated cells.
This striking result suggests that hepatocytes in particular
are more sensitive to the induction reprogramming than
other cells like fibroblasts or hematopoietic cells, probably
due to the fact that under physiological conditions they are
quiescent cells that rarely divide.The adult human liver how-
ever maintains a certain amount of plasticity, the hepatocytes
located in zones 1 and 2 of the liver lobule being, for instance,
capable of undergoing biliary reprogramming after injury
[30]. Moreover, we have shown here that malignant features
were more closely related to the influence of one of the
transgenes, themyc protooncogene.
4.3. The Influence of myc. MYC is at the crossroads of many
important biological pathways and processes involved in neo-
plastic cell growth and proliferation, promoting both iPSC
generation and carcinogenesis. In the developing human
gonad, germ cell differentiation, proliferation, and apopto-
sis must remain tightly controlled, in order to avoid the
malignant proliferation of stem cells. Oncogene and tumor
suppressor gene interplay is crucial. ES cells, carcinoma in situ
[31], and embryonal carcinoma all display similarities in gene
expression profiles [32], consistent with a limited window
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of transformation from primitive germ cells/gonocytes to
dormant precarcinoma in situ cells [33].
Previously, malignancy emerging from iPSC (ganglio-
neuroblastoma and follicular carcinoma of the thyroid) has
been attributed to myc retrovirus reactivation, leading the
authors to suggest replacement of the retrovirus-mediated
system by an adenovirus-mediated system, allowing transient
expression [34]. Here we further confirm that the generation
of pure embryonal carcinoma is related to the use of myc
during reprogramming. This link is stronger in hepatocyte-
derived iPSC and correlates with MYC expression in terms
of both staining intensity and percentage of positive cells, as
assessed by immunohistochemistry.
The tumors produced from hepatocyte-derived iPSC
reprogrammed withoutmyc showed a minor embryonal car-
cinoma component (∼10%), with only mild MYC immuno-
histochemical expression.The latter finding might be indica-
tive of amore advanced stage of differentiation, since terminal
differentiation results in decreased MYC expression [25].
Of note, small foci of fetal hepatocytes were part of the
teratoma elements. This was also the case when myc was
stably integrated in the transgenic 4F2A mice, confirming
that insertional mutagenesis is also a triggering factor.
For instance, one of the three CD34+ hematopoietic
stem cell-derived clones reprogrammedwith theOKS lentivi-
ral vector produced tumors with high malignant content,
consisting of embryonal carcinoma and yolk sac tumor. In
this case MYC reactivity was moderate in the embryonal
carcinoma component; since myc was not included in the
reprogramming vector, we believed these findings to be
related to insertional mutagenesis.
iPSC derived from 4F2A mouse hepatocytes and hema-
topoietic cells that had stably integrated the OKSM transgene
at the Rosa26 locus allowed teratoma formation with only
low levels of malignant structures, embryonal carcinoma foci
representing 5% to 10% of the tumor volume. MYC immuno-
histochemical positivity was only focal, mostly faint, and only
exceptionally moderate. No differences in tumor formation
were seen between iPSC derived from mouse hepatocytes
and hematopoietic cells. Other members of the Myc family
of genes, and more specifically l-myc, promote human iPSC
generation more effectively than c-myc and with weaker
malignant transformation activity [35]. Use of alternative
nonintegrative or integration-directed transgenes may there-
fore be beneficial for future clinical applications of iPSC
technologies.
Of note, incompletely reprogrammed, early-passage iPSC
that have not completely downregulated the expression of the
lentiviral vector encoded transcription factors used during
reprogramming (Nanog, Lin28, Sox2, and Oct4) have been
shown to generate malignant germ cell-like tumors [6]. The
presence of yolk sac tumor or embryonal carcinoma was
attributed to the reactivation of one or more transgenes used
during reprogramming [6]. We observed similar findings in
three clones generated from human fibroblasts injected after
the first passage (data not shown) when the OKSM lentiviral
vector had been used for reprogramming. The tumors gen-
erated were exclusively composed of embryonal carcinoma-
like foci. Immunohistochemical reactivity was similar to that
described for the clones generated from the reprogramming
of human hepatocytes, except for one tumor, which further
showed a partly nodular pattern of growth. In the nodules
only, despite strong SALL4, OCT4, and MYC reactivity,
pooled cytokeratins, CD30, and PLAP remained entirely
negative. These findings were suggestive of an even more
primordial and undifferentiated cell state within the nodules.
5. Conclusion
Since iPSC keep the epigenetic memory of the cells of ori-
gin, human hepatocytes would presumably be the best cell
source for potential therapeutic application in human liver
diseases. Yet we showed that clones derived from human
hepatocytes tend to produce tumors withmalignantmorpho-
logical features, including the propensity to develop metas-
tasis as exemplified by an intravascular tumor embolism.
This was not the case when fibroblasts or hematopoietic
cells were reprogrammed or when myc transgene was stably
integrated in the 4F2A mice cells. These findings suggest
that random integration of transgenes and the use of potent
protooncogenes such as myc would represent a greater risk
of malignant tumor development if hepatocytes are used
for reprogramming. Therefore nonviral vector delivery sys-
tems or reprogramming of cells obtained from less invasive
harvesting methods would represent interesting options for
future developments in stem cell-based approaches for liver
metabolic diseases.
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